Welcome to our dedicated page for Cytomx Therapeutics news (Ticker: CTMX), a resource for investors and traders seeking the latest updates and insights on Cytomx Therapeutics stock.
CytomX Therapeutics develops oncology biologics built on its PROBODY therapeutic platform, which masks and conditionally activates antibody-based therapies in the tumor microenvironment. News about CTMX commonly covers clinical updates for varsetatug masetecan, or Varseta-M, an EpCAM PROBODY ADC studied in advanced colorectal cancer and other EpCAM-expressing tumors, as well as CX-801, a masked Interferon-alpha-2b program initially developed in advanced melanoma.
Company updates also address financial results, research and development spending, cash runway, equity financings, and collaboration activity with Amgen, Regeneron, and Moderna. Recurring pipeline coverage includes dose-expansion data, combination-study activity, regulatory interactions, and PROBODY platform applications such as bispecific immunotherapies and T-cell engagers.
CytomX Therapeutics (Nasdaq: CTMX), a leader in masked, conditionally activated biologics, has announced its participation in two upcoming investor conferences in September 2024:
1. H.C. Wainwright 26th Annual Global Investment Conference: Scheduled for September 11, 2024, in New York, NY. CytomX will give a formal presentation at 12:30 p.m. ET.
2. 2024 Cantor Global Healthcare Conference: Set for September 19, 2024, also in New York, NY. The company will participate in a fireside chat at 9:45 a.m. ET.
Live webcasts of both events will be available on CytomX's website. The company's management will also be available for one-on-one meetings with registered conference attendees.
CytomX Therapeutics (Nasdaq: CTMX) reported Q2 2024 financial results and provided a business update. Key highlights include:
1. CX-904 (EGFR-CD3 PROBODY® T-cell engager) Phase 1a enrollment continues, focused on PDAC, NSCLC, and HNSCC, with a program update expected by end of 2024.
2. CX-2051 (EpCAM targeting PROBODY® ADC) Phase 1 study is enrolling its third cohort, with initial data anticipated in H1 2025.
3. CX-801 (interferon alpha-2b PROBODY® cytokine) Phase 1 study has its first clinical site active, with initial data expected in H2 2025.
4. Q2 2024 financial results: Revenue of $25.1 million, cash position of $137.2 million as of June 30, 2024.
5. Chris Ogden promoted to Chief Financial Officer.
CytomX Therapeutics (Nasdaq: CTMX), a leader in masked, conditionally activated biologic therapeutics, has announced it will report second quarter 2024 financial results on Thursday, August 8, 2024, after U.S. markets close. The company will host a conference call and webcast at 5:00 p.m. ET / 2:00 p.m. PT following the announcement. Investors can access the live webcast from CytomX's website and register for the conference call. Participants are advised to register at least 10 minutes before joining. An archived replay of the webcast will be available on the company's website for those unable to attend the live event.
CytomX Therapeutics (Nasdaq: CTMX) announced that CEO Sean McCarthy will participate in a fireside chat at the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference on June 25, 2024, at 2:00 p.m. ET. The event will be webcast live on CytomX’s website, where a recording will also be available. Management will be available for one-on-one meetings with registered investors during the conference.
CytomX Therapeutics has promoted Chris Ogden to Chief Financial Officer, effective June 15, 2024. Ogden has been with CytomX since August 2021, previously serving as Senior Vice President, Finance and Accounting.
Ogden brings extensive experience from his 16-year tenure at Eli Lilly, where he held senior financial roles, including CFO of Lilly Diabetes. He holds an M.B.A. from Harvard Business School.
CEO Sean McCarthy highlights Ogden's financial acumen and strategic leadership. Ogden expresses excitement about his new role and CytomX's mission to develop innovative cancer therapies.
CytomX Therapeutics, a leader in biologic therapeutics, will present at the Jefferies Global Healthcare Conference. Sean McCarthy, CEO and Chairman, is set to present on June 6, 2024, at 8:30 a.m. ET. The presentation will be live-streamed on CytomX’s website. Management will also conduct one-on-one meetings with registered investors.
CytomX Therapeutics, a leader in masked, conditionally activated biologics, granted stock options to two new employees on May 15, 2024. The options total 130,000 shares of the company’s common stock, priced at $1.96 per share, which was the closing price on the grant date. These options were granted under the company's 2019 Employment Inducement Incentive Plan, approved by the board in August 2020. The plan aims to attract new employees under Rule 5635(c)(4) of The Nasdaq Global Market.
CytomX Therapeutics announced positive initial data from the ongoing Phase 1a clinical study of CX-904, a masked PROBODY T-cell engager targeting EGFR in cancer patients. The drug showed a favorable safety profile with no CRS observed, promising anti-cancer activity in advanced pancreatic cancer, and encouraging pharmacokinetic results. Management plans to continue dose escalation and optimization, with further updates expected by the end of 2024.
CytomX Therapeutics reported positive initial Phase 1a dose escalation data for CX-904 in solid tumors, with ongoing dose escalation. Additionally, the first dose cohort for CX-2051 in solid tumors has been cleared, and the Phase 1 study continues. CX-801 is advancing to Phase 1 with a clinical collaboration agreement with Merck. The company achieved $10 million in milestones with Astellas. Financially, total revenue increased to $41.5 million, cash equivalents totaled $150.3 million, and research and development expenses increased slightly.
CytomX Therapeutics announced a clinical collaboration with Merck to evaluate CX-801 in combination with KEYTRUDA in patients with advanced metastatic solid tumors. The Phase 1 first-in-human study is expected to start in the first half of 2024. CX-801 is a masked interferon-alpha2b cytokine designed to activate the immune tumor microenvironment while overcoming systemic toxicities.